June 25, 2021 10:29 AM EDT
R&D
FDA+

FDA push­es back de­ci­sions on Ab­b­Vie's Rin­voq sNDAs to fur­ther re­view a failed Pfiz­er tri­al

Zachary Brennan

Senior Editor

Safe­ty ques­tions re­lat­ed to the lu­cra­tive class of med­i­cines known as JAK in­hibitors are con­tin­u­ing to slow the push to ex­pand their la­bels.

Ab­b­Vie on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times